BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31025094)

  • 1. The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.
    Veenstra C; Karlsson E; Mirwani SM; Nordenskjöld B; Fornander T; Pérez-Tenorio G; Stål O
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1845-1856. PubMed ID: 31025094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.
    Karlsson E; Veenstra C; Emin S; Dutta C; Pérez-Tenorio G; Nordenskjöld B; Fornander T; Stål O
    Breast Cancer Res Treat; 2015 Aug; 153(1):31-40. PubMed ID: 26208487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer.
    Karlsson E; Veenstra C; Gårsjö J; Nordenskjöld B; Fornander T; Stål O
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):599-607. PubMed ID: 30515568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.
    Shields BJ; Wiede F; Gurzov EN; Wee K; Hauser C; Zhu HJ; Molloy TJ; O'Toole SA; Daly RJ; Sutherland RL; Mitchell CA; McLean CA; Tiganis T
    Mol Cell Biol; 2013 Feb; 33(3):557-70. PubMed ID: 23166300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cell type-specific role of protein tyrosine phosphatase non-receptor type 2 in regulating ER stress signalling.
    Kasper SH; Spalinger MR; Raselli T; Scharl M
    Digestion; 2015; 91(3):248-56. PubMed ID: 25823847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TYRO3 as a potential therapeutic target in breast cancer.
    Ekyalongo RC; Mukohara T; Funakoshi Y; Tomioka H; Kataoka Y; Shimono Y; Chayahara N; Toyoda M; Kiyota N; Minami H
    Anticancer Res; 2014 Jul; 34(7):3337-45. PubMed ID: 24982338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of epithelial barrier function by the Crohn's disease associated gene protein tyrosine phosphatase n2.
    Scharl M; Paul G; Weber A; Jung BC; Docherty MJ; Hausmann M; Rogler G; Barrett KE; McCole DF
    Gastroenterology; 2009 Dec; 137(6):2030-2040.e5. PubMed ID: 19818778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 25-Hydroxyvitamin D
    Zhang P; Zhang W; Zhang D; Wang M; Aprecio R; Ji N; Mohamed O; Li Y; Ding Y; Wang Q
    J Periodontal Res; 2018 Jun; 53(3):467-477. PubMed ID: 29516520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
    Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
    J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
    Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX
    J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells.
    Huang Z; Liu M; Li D; Tan Y; Zhang R; Xia Z; Wang P; Jiao B; Liu P; Ren R
    J Biol Chem; 2020 Dec; 295(52):18343-18354. PubMed ID: 33122197
    [No Abstract]   [Full Text] [Related]  

  • 14. Met and its ligand HGF are associated with clinical outcome in breast cancer.
    Veenstra C; Pérez-Tenorio G; Stelling A; Karlsson E; Mirwani SM; Nordensköljd B; Fornander T; Stål O
    Oncotarget; 2016 Jun; 7(24):37145-37159. PubMed ID: 27175600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society.
    Ryu JM; Yu J; Kim SI; Kim KS; Moon HG; Choi JE; Jeong J; Do Byun K; Nam SJ; Lee JE; Lee SK; Kim SW
    Breast Cancer Res Treat; 2017 Dec; 166(3):833-842. PubMed ID: 28831642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulated PTPN2 induced by inflammatory response or oxidative stress stimulates the progression of thyroid cancer.
    Zhang Z; Xu T; Qin W; Huang B; Chen W; Li S; Li J
    Biochem Biophys Res Commun; 2020 Jan; 522(1):21-25. PubMed ID: 31735335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Descriptive analysis of molecular subtypes in Tunisian breast cancer.
    Fourati A; Boussen H; El May MV; Goucha A; Dabbabi B; Gamoudi A; Sfar R; Rahal K; El May A; Ben Abdallah M
    Asia Pac J Clin Oncol; 2014 Jun; 10(2):e69-74. PubMed ID: 23176549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype.
    Chung YR; Kim H; Park SY; Park IA; Jang JJ; Choe JY; Jung YY; Im SA; Moon HG; Lee KH; Suh KJ; Kim TY; Noh DY; Han W; Ryu HS
    Hum Pathol; 2015 Jul; 46(7):1027-35. PubMed ID: 26004371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
    Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
    Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.